Summary
GBI Research, the
leading business intelligence provider, has released its latest research,
"Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 -
Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and
Recurrent GBM", which provides in-depth analysis of the Glioblastoma
Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region,
covering Australia, China, India and Japan. The report provides estimates of
market size for 2013, along with market forecasts until 2020. It also covers
disease epidemiology, treatment algorithms, treatment patterns, and in-depth
analysis of the marketed and pipeline products.
The value of the GBM
market in the APAC region amounted to an estimated $49.4m in 2013, and is
expected to register a Compound Annual Growth Rate (CAGR) of 11.5%, to reach
$105.8m by 2020. The GBM market in India was the smallest of the APAC markets
in 2013, but is expected to experience the highest growth rate in the forecast
period, at a CAGR of 14.4%, due to having the highest number of promising
candidates in the pipeline. Japan currently has the largest share of GBM market
in the APAC region, at 48%, and is expected to experience healthy growth during
the forecast period at a CAGR of 13.8%.
Click for report details:
http://www.radiantinsights.com/research/glioblastoma-multiforme-therapeutics-in-asia-pacific-markets-to-2020-novel-therapeutic-approaches-target-high-unmet-need-in-newly-diagnosed-and-recurrent-gbm
The existing treatment
landscape is bleak for both newly diagnosed and recurrent GBM, with
temozolomide alone serving as the standard of care after surgery and radiation.
For first-line treatment Rindopepimut, a novel vaccine, is in late-stage
development in India and Australia, but it is limited to EGFRvIII patients.
There are two strong candidates in the current pipeline for second-line
treatment: Avastin and Cotara. Avastin is the first and only targeted therapy
for newly diagnosed GBM, is already approved as second-line treatment in
Australia and Japan, and is in Phase III development in China and India. Cotara
is a single-infusion drug with a novel delivery route, which is in Phase II
development in India. The expected launch of these three drugs is the key driver
for growth in APAC GBM market. As all are expensive, even a modest uptake will
increase the annual cost of therapy, and subsequently the market size.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment